- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07458347
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a first-in-human, phase 1, open-label, multicenter clinical trial designed to evaluate safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics and preliminary activity of orally administered KST-6051 as monotherapy or in combination with other anticancer agents. The trial seeks to enroll adults with advanced or metastatic KRAS mutant solid tumors including but not limited to pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer whose cancers have progressed after prior therapy or in whom standard therapy was not tolerated. The trial includes a dose escalation phase in which higher doses of KST-6051 will be given in subsequent groups of participants. The trial also includes a dose expansion phase to further investigate KST-6051. Participants can stay in the trial as long as they benefit from the treatment and can tolerate it.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Kestrel Therapeutics, Inc.
- Telefonnummer: 617-612-6810
- E-post: clinicaltrials@kestreltherapeutics.com
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Rekrytering
- Cedars-Sinai Medical Center
-
-
Florida
-
Sarasota, Florida, Förenta staterna, 34232
- Rekrytering
- Florida Cancer Specialists
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Mass General Brigham Cancer Institute at Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Rekrytering
- Sidney Kimmel Cancer Center
-
Kontakt:
- Ask Phase 1 (central mailbox)
- Telefonnummer: Please email:
- E-post: AskPhase1@jefferson.edu
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- The University of Texas MD Anderson Cancer Center
-
Kontakt:
- David Hong, MD
- Telefonnummer: Please email:
- E-post: dshong@mdanderson.org
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- NEXT Oncology
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Rekrytering
- Huntsman Cancer Institute, University of Utah
-
Kontakt:
- Susan Sharry, CCRP
- Telefonnummer: 801-585-3453
- E-post: susan.sharry@hci.utah.edu
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Rekrytering
- NEXT Virginia
-
Kontakt:
- Carrie Friedman, RN, BSN, OCN
- Telefonnummer: 703-636-1473
- E-post: carrie.friedman@usoncology.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years.
- Willing and able to give written informed consent.
- Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor.
- Documentation of KRAS mutation prior to the first dose of trial drug(s).
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- Adequate cardiovascular, hematological, liver, and renal function.
- Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).
Exclusion Criteria:
- Central nervous system (CNS) tumors or untreated or unstable metastases.
- Inability to swallow oral medications.
- Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Other inclusion/exclusion criteria are specified in the protocol.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: KST-6051 Dose Escalation Monotherapy
Sequential cohorts with increasing doses of KST-6051 as monotherapy will be evaluated to determine recommended dose(s) for expansion (RDE[s]). |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of gemcitabine/nab-paclitaxel will be evaluated in participants with previously treated PDAC. |
KST-6051 will be administered orally as a tablet. Gemcitabine/nab-paclitaxel will be administered intravenously (IV). |
|
Experimentell: KST-6051 Dose Escalation Combination Therapy with Cetuximab
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of cetuximab will be evaluated in participants with previously treated KRAS-mutant mCRC. |
KST-6051 will be administered orally as a tablet. Cetuximab will be administered IV. |
|
Experimentell: KST-6051 Dose Escalation Combination Therapy with Pembrolizumab
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of pembrolizumab will be evaluated in participants with first- or second-line KRAS-mutant NSCLC. |
KST-6051 will be administered orally as a tablet. Pembrolizumab will be administered IV. |
|
Experimentell: KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in PDAC after 1 or 2 prior lines of therapy. |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in mCRC after 1 or 2 prior lines of therapy. |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in NSCLC after 1 or 2 prior lines of therapy. |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in prior RAS/KRAS inhibitor-treated solid tumors. |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Expansion Monotherapy in Later-line Settings
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in selected KRAS-mutant biliary tract cancer, endometrial cancer (EC), or other solid tumors in later-line settings. |
KST-6051 will be administered orally as a tablet. |
|
Experimentell: KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with gemcitabine/nab-paclitaxel in 1L PDAC. |
KST-6051 will be administered orally as a tablet. Gemcitabine/nab-paclitaxel will be administered intravenously (IV). |
|
Experimentell: KST-6051 Dose Expansion Combination Therapy with Cetuximab
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab in 2L/3L CRC. |
KST-6051 will be administered orally as a tablet. Cetuximab will be administered IV. |
|
Experimentell: KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab and mFOLFOX6 or FOLFIRI in 1L CRC. |
KST-6051 will be administered orally as a tablet. Cetuximab will be administered IV. mFOLFOX6 will be administered IV. FOLFIRI will be administered IV. |
|
Experimentell: KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with pembrolizumab and pemetrexed/carboplatin in 1L NSCLC. |
KST-6051 will be administered orally as a tablet. Pembrolizumab will be administered IV. Pemetrexed will be administered IV. Carboplatin will be administered IV. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)
Tidsram: Up to Day 21 of Treatment Cycle 1
|
Up to Day 21 of Treatment Cycle 1
|
|
|
Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsram: Up to approximately 2 years
|
Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events. |
Up to approximately 2 years
|
|
Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)
Tidsram: Up to approximately 2 years
|
Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events. |
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Dose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 Alone
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: Cmax of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 Alone
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: Tmax of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: Half-life (t1/2) of KST-6051 Alone
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 Alone
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: AUC of KST-6051 in Combination with Other Agents
Tidsram: Up to Week 6
|
Up to Week 6
|
|
Dose Escalation Cohorts: ORR
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Escalation and Dose Expansion Cohorts: Overall Survival (OS)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Escalation Cohorts: Duration of Stable Disease
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Time to Response (TTR)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Number of Participants With TEAEs
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and Discontinuations
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Relative Dose Intensity and Treatment Exposure
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Dose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose Administration
Tidsram: Up to Week 6
|
Up to Week 6
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Patologiska processer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Gallvägssjukdomar
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Neoplastiska processer
- Genitala neoplasmer, hona
- Carcinom
- Uterina neoplasmer
- Patologiska tillstånd, tecken och symtom
- Rektal neoplasmer
- Neoplasmer i gallvägarna
- Lungneoplasmer
- Kolorektala neoplasmer
- Kolonneoplasmer
- Neoplasma Metastas
- Pankreatiska neoplasmer
- Kolangiokarcinom
- Endometriella neoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Koordinationskomplex
- Guanin
- Hypoxantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyror, sur
- Aminosyror
- Aminosyror, dikarboxyl
- Pemetrexed
- Cetuximab
- Karboplatin
- pembrolizumab
- IFL -protokollet
Andra studie-ID-nummer
- KST-6051-101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .